Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapyThomas Georgi, Vladan Vučinić, Timm Denecke et al.|Journal of Cancer Research and Clinical Oncology|2023Cited by 25
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two CasesKristin Gerhardt, Vladan Vučinić, Madlen Jentzsch et al.|Frontiers in Oncology|2021Cited by 6
Rapid Response to Idecabtagene Vicleucel in a Myeloma Patient Refractory to Multiple Prior Lines of Anti-BCMA Directed TherapiesMaximilian Merz, Uwe Platzbecker, Vladan Vučinić et al.|Blood|2022Cited by 1
Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes - No Association of Clonal Hematopoiesis (CH) with Manufacturing SuccessSimon M. Krauß, Vladan Vučinić, Konstantin Weibl et al.|Blood|2022Cited by 0
Cellular dynamics and their impact on outcome in patients with mantle cell lymphoma during treatment with chimeric antigen receptor (CAR) T cellsR. Weiß, Vladan Vučinić, C. P. Fernandez et al.|Hematological Oncology|2023Cited by 0